SynthesisFrontiers in endocrinology2026
Association between spexin and type 2 diabetes mellitus: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accumulating evidence suggests that spexin is implicated in cellular energy balance, glucose and lipid metabolism, appetite suppression, and water-electrolyte regulation, and is closely associated with metabolic conditions including obesity, hyperglycemia, and hyperlipidemia. However, due to limitations in sample size, ethnic diversity among study populations, and variability in clinical study designs, existing findings on the association between spexin and Type 2 diabetes mellitus (T2DM) remain inconsistent. Aim: This meta-analysis aimed to statistically evaluate the level of spexin in patients with T2DM. Methods: A systematic literature search was conducted across five electronic databases (PubMed, Web of Science, OVID, Elsevier Science Direct, and Wiley Online Library). The search strategy targeted the terms "spexin" in conjunction with "Type 2 diabetes mellitus" or "T2DM" in title and abstract fields. Results are presented as standardized mean differences (SMD) with 95% confidence intervals (CI). Results: Eleven articles (1,122 cases and 681 controls) were included in the meta-analysis. The results of the meta-analysis indicated that the circulating spexin in patients with T2DM was significantly lower than that of the controls (SMD: -2.32, 95% CI: -3.32, -1.31). Conclusions: This meta-analysis is the first to comprehensively evaluate the level of circulating spexin in patients with T2DM. Given the substantial heterogeneity observed, the conclusions should be interpreted with caution. Future studies with standardized methodologies are needed to validate our findings and investigate the potential mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.